| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $1,209,113 ) |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA221874 | Comprehensive minimal residual disease tracking in cancer | 000 | 5 | NIH | 11/4/2024 | $399,996 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K01DK132455 | The Role of Mitochondrial TNAP in Adaptive Thermogenesis | 000 | 3 | NIH | 11/13/2024 | $127,781 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R37CA269990 | Mechanisms by which LSD1 Promotes Neuroendocrine Differentiation and Small Cell Lung Cancer | 000 | 3 | NIH | 11/6/2024 | $420,355 |
| | 2025 | 2025 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01AI165442 | Identification of Metabolic and Immune Deficits in the Aged Population and Their Restoration to Achieve Youthful Anti-Influenza Vaccine Responsiveness | 000 | 4 | NIH | 11/5/2024 | $1,169,078 |
| | 2025 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA188446 | A novel flat-panel detector for advanced on-board radiation therapy imaging | 000 | 10 | NIH | 11/14/2024 | $0 |
| | 2025 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U24HG011451 | Generating a full-length reference transcriptome for human protein-coding genes | 000 | 3 | NIH | 11/6/2024 | $0 |
| | 2025 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA229261 | Dissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint Inhibition | 000 | 5 | NIH | 11/1/2024 | $0 |
| | 2025 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35GM131802 | Data Analysis Tools for Emerging High-Throughput Technologies | 000 | 5 | NIH | 11/7/2024 | $0 |
| | 2025 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U54CA231638 | The Center for Synovial Sarcoma Biology and Therapeutics | 000 | 1 | NIH | 11/5/2024 | -$49,057 |
| | 2025 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P50CA100707 | SPORE in Multiple Myeloma | 000 | 20 | NIH | 10/11/2024 | -$552,410 |
| | 2025 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA263555 | The Impact of Donor Hematopoietic DNMT3A Mutations in Stem Cell Transplant Recipients | 000 | 3 | NIH | 10/23/2024 | -$31,808 |
| | 2025 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K08CA279918 | Fast-kinetics approaches to define direct gene-regulatory functions of MYB in leukemia | 000 | 1 | NIH | 10/8/2024 | -$204,053 |
| | 2025 | 2023 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA279915 | Defining PRC1.1 as a gatekeeper of lineage plasticity and response to anti-GD2 therapy | 000 | 1 | NIH | 10/11/2024 | -$6,832 |
| | 2025 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | UH3AG060626 | Improving Advance Care Planning in Oncology: A Pragmatic, Cluster-Randomized Trial Integrating Patient Videos and Clinician Communication Training | 000 | 5 | NIH | 11/5/2024 | $0 |
| | 2025 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA227640 | KDM5 histone lysine demethylases as potential novel myeloid tumor suppressors | 000 | 5 | NIH | 11/5/2024 | -$1 |
| | 2025 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U54CA231637 | The Center for Therapeutic Targeting of EWS-oncoproteins | 000 | 1 | NIH | 11/5/2024 | -$579 |
| | 2025 | 2022 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K07CA222159 | Obesity and Pancreatic Cancer Progression and Survival | 000 | 5 | NIH | 11/5/2024 | $0 |
| | 2025 | 2021 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA245897 | Uncovering Principles of Adaptive Regulation in Cancer Resistance Through Deep Evolutionary Profiling | 000 | 2 | NIH | 10/17/2024 | $0 |
| | 2025 | 2019 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01DE029188 | Defining mechanisms of immunotherapy resistance in head and neck squamous cell carcinomas | 000 | 1 | NIH | 10/1/2024 | -$63,357 |
|
| Issue Date FY: 2024 ( Subtotal = $163,843,002 ) (Continued on the next page) |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R35CA197583 | Dissecting and Targeting Deregulated Mitochondrial Apoptosis in Human Cancer | 000 | 11 | NIH | 7/18/2024 | $999,639 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA274276 | Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity | 000 | 3 | NIH | 8/12/2024 | $985,172 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01CA206978 | Comprehensive dissection of the CLL genome & phenome to improve patient outcomes | 000 | 9 | NIH | 8/29/2024 | $1,546,492 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99CA279888 | Targeting Menin Protein Stability In AML | 000 | 2 | NIH | 3/12/2024 | $129,600 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI158488 | CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans | 000 | 4 | NIH | 3/7/2024 | $400,500 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA240804 | Translation of a Bismuth-Gadolinium Nanoparticle for MR-guided Radiation Therapy | 001 | 5 | NIH | 4/24/2024 | $29,801 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA213404 | Polyploidy, Aneuploidy and Genome Stability | 001 | 26 | NIH | 4/16/2024 | $26,432 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI158488 | CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans | 001 | 4 | NIH | 5/23/2024 | $44,500 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA246648 | A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors | 001 | 3 | NIH | 8/30/2024 | $695,558 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA246648 | A web-based patient-reported symptom monitoring and self-management portal for adolescent and young adult breast cancer survivors | 002 | 3 | NIH | 9/3/2024 | $222,678 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA213404 | Polyploidy, Aneuploidy and Genome Stability | 002 | 26 | NIH | 8/16/2024 | $0 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | P01CA250959 | New therapeutic vulnerabilities in breast cancer | 000 | 5 | NIH | 7/22/2024 | $1,666,032 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA272657 | Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer | 000 | 3 | NIH | 8/6/2024 | $411,213 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA213404 | Polyploidy, Aneuploidy and Genome Stability | 000 | 26 | NIH | 11/16/2023 | $475,795 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01GM152499 | Survival Data Analysis using general censoring-free incident rate | 000 | 1 | NIH | 2/15/2024 | $347,254 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01GM152499 | Survival Data Analysis using general censoring-free incident rate | 001 | 1 | NIH | 4/8/2024 | $0 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA281840 | Immunotherapeutic targeting of gangliosides in Ewing Sarcoma | 000 | 2 | NIH | 8/14/2024 | $755,393 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA262577 | Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studies | 000 | 3 | NIH | 8/14/2024 | $640,260 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA249185 | Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications | 000 | 4 | NIH | 7/19/2024 | $385,461 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R50CA265182 | Molecular origins and evolution to treatment resistance in genitourinary cancers | 000 | 3 | NIH | 8/7/2024 | $330,413 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01AI165666 | Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases | 001 | 2 | NIH | 7/17/2024 | $664,312 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA274597 | Elucidating the role of RNA splicing in the metastatic seeding and outgrowth of aggressive cancers. | 001 | 3 | NIH | 7/26/2024 | $6,912 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | R01CA293092 | Harnessing naturally occurring cell type-specific regulatory elements and normal HSC hematopoiesis to develop cell lineage-controlled CAR expression and continuously renewing CAR NK cells | 000 | 1 | NIH | 7/25/2024 | $513,859 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | U01CA294507 | Myeloma multidimensional precancer atlas | 000 | 1 | NIH | 9/18/2024 | $1,128,990 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | DP5OD029637 | Dissecting the interaction between DNA damage repair defects and the tumor microenvironment | 001 | 5 | NIH | 8/29/2024 | $1 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | DP5OD029637 | Dissecting the interaction between DNA damage repair defects and the tumor microenvironment | 001 | 5 | NIH | 8/29/2024 | $442,499 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K99HG012798 | Robust and cost-effective computational methods for haplotype-resolved genome assemblies | 001 | 2 | NIH | 9/23/2024 | -$79,374 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284291 | Fertility legislation and unmet needs: Exploring intervenable barriers for quality oncofertility care among adolescent and young adult cancer patients | 001 | 2 | NIH | 6/13/2024 | $92,304 |
| | 2024 | 2024 | DANA-FARBER CANCER INSTITUTE, INC. | 450 BROOKLINE AVE | BOSTON | MA | 02215-5418 | SUFFOLK | USA | K00CA284291 | Fertility legislation and unmet needs: Exploring intervenable barriers for quality oncofertility care among adolescent and young adult cancer patients | 001 | 2 | NIH | 6/13/2024 | -$92,664 |
|
